ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal Women with Early-Stage Breast Cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, December 12, 2019 – Agendia, Inc., a world leader in precision oncology for Read More
Agendia to Present New Data at SABCS 2019 Demonstrating How Comprehensive Genomic Profiling Benefits Early-Stage Breast Cancer Patients
PRESS RELEASE Data evaluating MammaPrint® and BluePrint® includes new risk analysis of premenopausal women with breast cancer, and insights into unique characteristics among specific populations of breast cancer patients IRVINE, CALIF. – 19 November Read More
Agendia Presents New Data on the Biological Characteristics of Patients within Extreme Low Risk and High Risk MammaPrint Subgroups at the European Society for Medical Oncology (ESMO)
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 29 September 2019 – Agendia, Inc., a world leader in precision oncology for breast cancer, will present new data from their on-going clinical research at Read More
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using Read More